Explore

Trendline Trendline
FDA Alignment and AI Integration Critical for Rare Disease Drug Development

FDA Alignment and AI Integration Critical for Rare Disease Drug Development

FDA Alignment and AI Integration Critical for Rare Disease Drug Development
Trendline Trendline
ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage
Trendline Trendline
Biogen's Alzheimer's Drug Results Support Tau Theory, Boosting Denali's Prospects

Biogen's Alzheimer's Drug Results Support Tau Theory, Boosting Denali's Prospects

Biogen's Alzheimer's Drug Results Support Tau Theory, Boosting Denali's Prospects
Trendline Trendline
Biogen's Alzheimer's Drug Advances Tau Theory, Boosts Denali's Prospects

Biogen's Alzheimer's Drug Advances Tau Theory, Boosts Denali's Prospects

Biogen's Alzheimer's Drug Advances Tau Theory, Boosts Denali's Prospects
Trendline Trendline
Biogen Advances Alzheimer's Drug Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Despite Phase 2 Trial Setback
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges
Trendline Trendline
Biogen's Alzheimer's Drug Diranersen Moves to Phase 3 Despite Phase 2 Setbacks

Biogen's Alzheimer's Drug Diranersen Moves to Phase 3 Despite Phase 2 Setbacks

Biogen's Alzheimer's Drug Diranersen Moves to Phase 3 Despite Phase 2 Setbacks
Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism
Trendline Trendline
Biogen's Phase 2 Tau Study Shows Promise in Alzheimer's Treatment

Biogen's Phase 2 Tau Study Shows Promise in Alzheimer's Treatment

Biogen's Phase 2 Tau Study Shows Promise in Alzheimer's Treatment
Trendline Trendline
Kariya and NeuraLight Collaborate to Advance GLP-1 Therapies for Neurodegeneration

Kariya and NeuraLight Collaborate to Advance GLP-1 Therapies for Neurodegeneration

Kariya and NeuraLight Collaborate to Advance GLP-1 Therapies for Neurodegeneration
Trendline Trendline
Tempus and Bristol Myers Squibb Partner to Enhance Clinical Development in Oncology and Neuroscience

Tempus and Bristol Myers Squibb Partner to Enhance Clinical Development in Oncology and Neuroscience

Tempus and Bristol Myers Squibb Partner to Enhance Clinical Development in Oncology and Neuroscience
Trendline Trendline
Fosun Pharma and AriBio Partner for Alzheimer's Drug Development

Fosun Pharma and AriBio Partner for Alzheimer's Drug Development

Fosun Pharma and AriBio Partner for Alzheimer's Drug Development